Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research (Excluding Clinical Trials)

Abstract 4258: Genetic profiling of breast cancer confirms a pivotal Role of EGFR pathway in the development of acquired resistance to Tamoxifen in locally recurrent and metastatic breast cancer patients

Abdel-Rahman N. Zekri, Abeer Bahnassy, Ibrahim Malash, Mohammad Mansour, Sabry Shaarawy, Hoda Abdel-Raouf and Rabab Gaafar
Abdel-Rahman N. Zekri
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abeer Bahnassy
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ibrahim Malash
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Mansour
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabry Shaarawy
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hoda Abdel-Raouf
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rabab Gaafar
National Cancer Inst. Cairo Univ., Cairo, Egypt.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-4258 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

Background: Acquisition of resistance to Tamoxifen is a major drawback in the treatment of estrogen receptor (ER)-positive breast cancer (BC) patients. The role of CYP2D6 in predicting response to Tamoxifen is debatable. We assessed the involvement of aberrant EGFR pathway genes expressions and CYP2D6 polymorphism in predicting response to Tamoxifen in a cohort of BC patients from Egypt.

Patients and methods: This prospective study included 157 females with hormone receptor positive, locally recurrent inoperable and/or metastatic BC patients treated in the National Cancer Institute, Cairo. Patients were categorized according to their response to Tamoxifen into: responders and refractory groups. RNA and DNA were extracted from tumour and normal tissue samples obtained from all patients. The expression of 92 genes in the EGFR pathway was evaluated using the SABioscience array (Qiagen) with four house-keeping genes and CYP2D6 polymorphism was assessed by PCR.

Results: We found that 58.6% of the patients were ER/PR positive, 32.48% were ER positive and 8.91% were PR positive. Response to Tamoxifen correlated significantly with the site of the disease (patients with bone only disease demonstrated better and maintained response compared to those with visceral involvement; p. = 0.005) and CYP2D6 polymorphism (p. = 0.034). CYP2D6 *3, *4 were significantly prevalent in the refractory group (86.6%), whereas variants *10/*10 and *10/*3 were more common in the in the responders (85.5%) (p. = 0.027). RNA profiling of the EGFR pathway showed that 56 genes were differentially over-expressed in the refractory group compared to the responders, of which only JAK1, COL1A1, GAB1, FN1, MKNK1, AKT1, EGFR, NFKB1 and HGDC showed a significant difference between the groups (p<0.05).. Thirty four genes were differentially reduced, of which only STAT5A, RHOA, MAPK9, MAPK10, CCND1 showed significant difference between groups (p<0.05)..

Conclusion: The EGFR pathway contributes significantly to patients’ response to Tamoxifen in locally advanced/ metastatic breast cancer. A panel of 13 genes (JAK1, COL1A1, GAB1, FN1, MKNK1, EGFR, NFKB1, HGDC, STAT5A, RHOA, MAPK9, MAPK10, CCND1) in this pathway together with CYP2D6 polymorphisms can predict response to Tamoxifen though this has to be verified in a larger study.

Citation Format: Abdel-Rahman N. Zekri, Abeer Bahnassy, Ibrahim Malash, Mohammad Mansour,Sabry Shaarawy, Hoda Abdel-Raouf, Rabab Gaafar. Genetic profiling of breast cancer confirms a pivotal Role of EGFR pathway in the development of acquired resistance to Tamoxifen in locally recurrent and metastatic breast cancer patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4258. doi:10.1158/1538-7445.AM2015-4258

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 4258: Genetic profiling of breast cancer confirms a pivotal Role of EGFR pathway in the development of acquired resistance to Tamoxifen in locally recurrent and metastatic breast cancer patients
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 4258: Genetic profiling of breast cancer confirms a pivotal Role of EGFR pathway in the development of acquired resistance to Tamoxifen in locally recurrent and metastatic breast cancer patients
Abdel-Rahman N. Zekri, Abeer Bahnassy, Ibrahim Malash, Mohammad Mansour, Sabry Shaarawy, Hoda Abdel-Raouf and Rabab Gaafar
Cancer Res August 1 2015 (75) (15 Supplement) 4258; DOI: 10.1158/1538-7445.AM2015-4258

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 4258: Genetic profiling of breast cancer confirms a pivotal Role of EGFR pathway in the development of acquired resistance to Tamoxifen in locally recurrent and metastatic breast cancer patients
Abdel-Rahman N. Zekri, Abeer Bahnassy, Ibrahim Malash, Mohammad Mansour, Sabry Shaarawy, Hoda Abdel-Raouf and Rabab Gaafar
Cancer Res August 1 2015 (75) (15 Supplement) 4258; DOI: 10.1158/1538-7445.AM2015-4258
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research (Excluding Clinical Trials)

  • Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas
  • Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)
  • Abstract LB-251: Development of a circulating microRNA risk signature predictive of breast cancer diagnosis among high-risk women
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas
  • Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)
  • Abstract LB-251: Development of a circulating microRNA risk signature predictive of breast cancer diagnosis among high-risk women
Show more 3

Poster Presentations - Genomics in the Clinic 1

  • Abstract 4268: DNA copy number variation and driver mutation patterns of follicular thyroid tumors
  • Abstract 4253: A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm
  • Abstract 4261: Oncomine® Cancer Panel: simultaneous detection of clinically relevant hotspot mutations, CNVs, and gene fusions in solid tumors
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement